原发性肝癌的免疫治疗进展

Primary hepatic carcinoma is a kind of important disease that seriously threatens human's life and is the second leading cause of malignant tumor related death in our country, with a 5-year survival rate of less than 5%. Currently, the main treatments for hepatocellular carcinoma are surgery, interventional chemoembolism and liver transplantation, etc. However, tumor recurrence and metastasis and advanced liver cancer treatment are still the urgent problem to be addressed. Cancer immunotherapy emerges as a new therapy with broad prospects in recent years. It achieves the purpose of slowing tumor progression and even curing tumour by improving immunological reaction, stimulate tumor-specific immune and breaking immune tolerance. Nowdays, several treatment regimens have been began to use in clinical and exhibit certain effect. Nevertheless, it is much used as auxiliary therapy or palliative care alternatives and the effect still needs to be improved. New researches and exploitations are expected to further improve immune therapy in clinical effectiveness and specificity. Thus, it may play a more important role in the future. In this paper, the the present status and progress of immunotherapy treatment for primary liver cancer are reviewed.